Interestingly, liquid biopsy analysis of PTEN genomic status within circulating tumor cells (CTCs) is also being investigated as a quick, non-invasive strategy to identify patients with PTEN-deficient prostate cancer, with a view to inform treatment decisions [74,75]. This evidence concerns the gene PTEN and neoplasm.